Real-World Data on Helicobacter pylori Treatment Success

Clinical Takeaway

: The good news: amoxicillin-containing regimens can still work well. The bad news: previous antibiotic use can compromise treatment efficacy.

Context

Helicobacter pylori treatment in the U.S. is complicated by two intertwined problems: rising rates of community antibiotic resistance, but almost no data on resistance pattens among H. pylori isolates. Recent guidelines endorse 14-day empirical therapy with a proton-pump inhibitor (PPI), bismuth, metronidazole, and tetracycline (PBMT-14), but other regimens are still often used.

In a retrospective cohort study, researchers evaluated outcomes among more than 25,000 patients treated for confirmed H. pylori infection in Northern California between 2000 and 2022.

Key Results

Among the 17 different regimens used for initial infection, the three most effective were 14-day combinations of PPI/amoxicillin/clarithromycin/metronidazole (90%), PBM…

Reviewing Author

Abigail Zuger, MD

Disclosures

Nothing to disclose